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Prescription, diversion, and illicit use of opioid therapeutics have
emerged as a major societal concern in recent years, fueling a
concerted effort to identify the neural basis of opioid dependence,
with the goal of developing more effective treatments for those
afflicted with substance use disorders. One question that continues
to be explored due to its substantial clinical implications is: to what
extent does opioid dosing and pharmacokinetics (continuous versus
interrupted opioid administration) influence abuse liability and
modify reward circuitry? The clinical relevance goes beyond the
desire to maintain analgesia while minimizing rescue medication to
treat breakthrough pain. A valuable lesson in appropriate dosing
was learned from Oxycontin® prescription recommendations, where
those taking this opioid often exhibited pseudo-addiction due to the
mis-guided marketing that the pharmacokinetic profile recom-
mended dosing every 12 h. In reality, the half-life of this extended
release formulation was much shorter, ranging from 4.5 to 9 h (SPC.
Oxycontin. https://www.accessdata.fda.gov/drugsatfda_docs/label/
2015/022272s027lbl.pdf). The lack of maintaining steady state
opioid plasma levels not only allowed break through pain to occur,
but likely generated stress and/or mild symptoms of withdrawal.
Thus, it is not unreasonable to assume that the inappropriate opioid
dosing contributed to the current climate of the opioid epidemic.
Preclinical research supports the idea that the lack of steady state
opioid plasma levels impacts drug-seeking behavior, where drug
regimens had dramatic effects on mesolimbic circuits, including
dopamine-dependent reward. Yu et al. [1] determined that while
both continuous versus intermittent morphine dosing produced
analgesic tolerance, only the intermittent morphine dosing facili-
tated subsequent morphine self-administration. In addition, Lee
et al. [2] recently reported that intermittent (but not continuous)
opioid administration induced neuroinflammation and dysregula-
tion of dopamine-dependent reward behaviors, which was causally
related to changes in gut microbiome.
In the current issue of Neuropsychopharmacology©, Lefevre
et al. [3] provide further insight to mechanisms underlying
opioid-induced adaptive changes in brain regions involved in
motivation, reinforcement, decision-making, and reward predic-
tion. They report that intermittent daily morphine (Q24h) causes
long-lasting psychomotor sensitization, whereas continuous
morphine (via infusion pump) produced the opposite effect
exhibiting locomotor tolerance. The phenomenon of locomotor
sensitization requires striatal dopamine release and is often used
as a proxy for assessing plasticity of reward circuitry [4]. To
eliminate the possibility that opioid plasma concentrations were
responsible for the different behavioral outcomes, the authors
administered twice daily naloxone (Q12h) to mice receiving
continuous morphine to recapitulate an intermittent dosing
paradigm. Interestingly, the dose-dependent locomotor sensiti-
zation effects persisted following a 10-day cessation of the initial
morphine, suggesting that it produced significant synaptic
plasticity in striatal circuitry. To determine if changes in basal
dopamine levels could account for the differences in locomo-
tor sensitization between the two dosing regimens, the Leferve
study used an elegant fiber photometry approach. They
expressed the genetically encoded dopamine sensor dLight1.3b
in the nucleus accumbens and measured the fluorescent signal
prior to and following different morphine dosing regimens.
Spontaneous fluorescent transient events were used to assess
baseline dopamine dynamics. Intermittent morphine increased
the amplitude of these events, whereas continuous morphine
reduced it, suggesting dynamic differences in dopamine
signaling and mesolimbic circuit activity.
The interesting commonality between many of the studies
that examined differences between continuous and intermittent
opioid dosing is that continuous opioid exposure, that produces
steady state blood and brain opioid levels, does not cause
significant dysregulation of the mesolimbic dopaminergic
circuit. Yet, dopamine-dependent behavior is modified when
opioid exposure is interrupted, presumably by imposing a state
of repeated acute withdrawal. According to Lefevre et al. [3]
patterns of opioid exposure elicit differences in the transcrip-
tome within the striatum, a key brain region involved in the
genesis of substance use disorders. Transcriptional profiling,
showed that intermittent, but not continuous, opioid exposure
altered mRNA expression of both excitatory and inhibitory
transmitter receptor subunits [3]. These changes may contribute
to the synaptic plasticity within mesolimbic circuitry that play a
role in addictive-like behaviors in animal models. One of the
modified transcripts highlighted in the Lefevre paper was heat
shock transcription factor 1 (HSF1), a DNA binding protein
activated following cellular stress. Inhibitors of HSF1 have been
pursued as a novel cancer treatment [5], and there is strong
evidence that HSF1 function is neuroprotective and reduced in
neurodegenerative disorders such as Alzheimer’s disease [6].
Further studies are required to define the potential of this target
in treating substance use disorders.
Is it possible that opioid dosing regimens partially explain reports
that opioid use can increase the risk of depression recurrence and
development of treatment-resistant depression even after control-
ling for pain, psychiatric disorder and opioid misuse (reviewed in
[7])? Intermittent (but not continuous) opioid dosing leads to
neuroinflammation [2], which can precipitate protracted abstinence
syndrome and negative mood states that is thought to drive drug
craving. Methadone maintenance therapy is effective because of its
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long half-life, which minimizes or eliminates the euphoric effects
associated with acute opioid use such as heroin or fentanyl. But
what if this explanation is an oversimplification. Maybe methadone
normalizes the striatal neuroplasticity and/or transcript changes
associated with opioid misuse due to its ability to maintain steady
state plasma levels. Indeed, methadone was shown to reduce
emotional and depressive reactivity in subjects on methadone
maintenance therapy [8]. Could the concept that dosing influences
reward circuitry be generalizable to other drugs of abuse? Clinical
trials assessing the effectiveness of methylphenidate for main-
tenance therapy to psychostimulant addiction show mixed results,
although there was some indication that it increased retention
in subjects with cocaine addiction [9], and improved depressed
mood [10].
In conclusion, the Lefreve study, and others like it, remind us
that choice of dose regimens influences outcomes, and that
modeling human drug use is critical if we are to understand the
underlying mechanisms that lead to substance use disorders and
comorbid diseases. Further, more studies are needed to under-
stand whether it is the stress per se (caused by repeated
withdrawal that accompanies the intermittent dosing regimen),
the learned association that subsequent drug use alleviates
negative affect and withdrawal, or another factor such as
neuroinflammation that sets up the perfect storm for addiction
susceptibility.
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